The Catalyst | DISRUPT CAD

New IVL Trilogy in JACC Interventions – Hear the Highlights

Posted by Emma Miller on Jun 28, 2021 8:41:44 AM

Learn about IVL’s unique mechanism of action in fracturing severe, superficial and deep calcium and the clinical outcomes associated with IVL in the coronary and peripheral vasculature.

0 Comments Click here to read/write comments

Topics: DISRUPT CAD, IVL Technology, DISRUPT PAD, Coronary Clinical Data, Peripheral Clinical Data

A Patient-level Pooled Analysis of the Disrupt CAD I, II, III and IV Studies: Q&A with Dr. Robert Riley

Posted by Emma Miller on May 17, 2021 3:10:59 PM

We had the privilege of connecting with Dr. Robert Riley Director, Complex Coronary Therapeutics Program, The Christ Hospital Health System. Dr. Riley is the leading author of the abstract for the Patient-Level Pooled Analysis of the Disrupt CAD I, II, III and IV studies and presented at ACC.21 Virtual.

0 Comments Click here to read/write comments

Topics: Coronary IVL, DISRUPT CAD, Coronary Cases, Coronary Clinical Data, Shockwave C2, Coronary Conferences

CAD III ShockTalk: A Discussion about the Data’s Significance

Posted by Emma Miller on Dec 29, 2020 1:49:53 PM

At TCT Connect, investigators presented the 30-day primary endpoint analysis of the Disrupt CAD III study, the largest and most rigorous coronary IVL study to date.

0 Comments Click here to read/write comments

Topics: Coronary IVL, DISRUPT CAD, Coronary Cases, Coronary Clinical Data

DISRUPT CAD III Q&A with Co-PI Dr. Jonathan Hill

Posted by Emma Miller on Oct 15, 2020 9:35:37 AM

Following its presentation as a late-breaking clinical at TCT Connect and simultaneous publication in the Journal of the American College of Cardiology (JACC) we sat down with Dr. Jonathan Hill, Consultant Cardiologist at the Royal Brompton Hospital in London, to get his perspective on the results, how they build on CAD I & II outcomes, and where they fit into clinician’s daily decision-making process when treating calcified lesions. We hope you enjoy his perspective.

0 Comments Click here to read/write comments

Topics: Coronary IVL, DISRUPT CAD, Coronary Clinical Data, Shockwave C2, Coronary Conferences

Q&A: Dr. Kereiakes Shares Perspective on DISRUPT CAD III Design

Posted by Emma Miller on Aug 26, 2020 9:01:31 AM

Last month the DISRUPT CAD III investigators, led by co-PIs Drs. Dean Kereiakes and Jonathan Hill, published in the American Heart Journal the trial design and rationale paper titled, “Evaluation of safety and efficacy of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: Design and rationale for the Disrupt CAD III trial.”

0 Comments Click here to read/write comments

Topics: Coronary IVL, DISRUPT CAD, Coronary Clinical Data

It’s Good to Be Eccentric…When Trying to Treat Eccentric Calcium

Posted by Emma Miller on Jul 1, 2020 1:07:09 PM

If Shockwave IVL had a personality, we’d like to think that we’d be a bit on the eccentric side. A little unconventional and taking a slightly different path than everyone else. After all, you won’t be successful in introducing a new disruptive technology if you’re marching to the same drumbeat as everyone else.

0 Comments Click here to read/write comments

Topics: DISRUPT CAD, Coronary Cases, Shockwave C2, Coronary Conferences, CAD Applications - Eccentric Lesions